Neurobo Pharmaceuticals Performance
| NRBODelisted Stock | USD 1.89 0.11 5.50% |
The company secures a Beta (Market Risk) of -0.69, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Neurobo Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Neurobo Pharmaceuticals is likely to outperform the market. At this point, Neurobo Pharmaceuticals has a negative expected return of -0.35%. Please make sure to verify Neurobo Pharmaceuticals' value at risk, daily balance of power, as well as the relationship between the Daily Balance Of Power and price action indicator , to decide if Neurobo Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Neurobo Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental drivers remain very healthy which may send shares a bit higher in March 2025. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
| Begin Period Cash Flow | 33.4 M |
Neurobo |
Neurobo Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 236.00 in Neurobo Pharmaceuticals on November 27, 2024 and sell it today you would lose (47.00) from holding Neurobo Pharmaceuticals or give up 19.92% of portfolio value over 90 days. Neurobo Pharmaceuticals is currently does not generate positive expected returns and assumes 6.0132% risk (volatility on return distribution) over the 90 days horizon. In different words, 53% of stocks are less volatile than Neurobo, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Neurobo Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Neurobo Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Neurobo Pharmaceuticals, and traders can use it to determine the average amount a Neurobo Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0583
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | NRBO |
Estimated Market Risk
| 6.01 actual daily | 53 53% of assets are less volatile |
Expected Return
| -0.35 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.06 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Neurobo Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Neurobo Pharmaceuticals by adding Neurobo Pharmaceuticals to a well-diversified portfolio.
Neurobo Pharmaceuticals Fundamentals Growth
Neurobo Stock prices reflect investors' perceptions of the future prospects and financial health of Neurobo Pharmaceuticals, and Neurobo Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Neurobo Stock performance.
| Return On Equity | -1.61 | |||
| Return On Asset | -0.74 | |||
| Current Valuation | (1.18 M) | |||
| Shares Outstanding | 8.62 M | |||
| Price To Earning | (1.44) X | |||
| Price To Book | 1.57 X | |||
| Revenue | 7 K | |||
| EBITDA | (15.88 M) | |||
| Cash And Equivalents | 8.85 M | |||
| Cash Per Share | 9.96 X | |||
| Total Debt | 203 K | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | 1.50 X | |||
| Cash Flow From Operations | (10.8 M) | |||
| Earnings Per Share | (4.29) X | |||
| Total Asset | 22.78 M | |||
| Retained Earnings | (108.27 M) | |||
| Current Asset | 21.62 M | |||
| Current Liabilities | 11.75 M | |||
About Neurobo Pharmaceuticals Performance
By examining Neurobo Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Neurobo Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Neurobo Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company that develops and commercializes multimodal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts. Neurobo Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 5 people.Things to note about Neurobo Pharmaceuticals performance evaluation
Checking the ongoing alerts about Neurobo Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Neurobo Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Neurobo Pharmaceuticals is now traded under the symbol MTVA. Please update your portfolios or report it if you believe this is an error. Report It! | |
| Neurobo Pharmaceuticals is not yet fully synchronised with the market data | |
| Neurobo Pharmaceuticals generated a negative expected return over the last 90 days | |
| Neurobo Pharmaceuticals has high historical volatility and very poor performance | |
| Neurobo Pharmaceuticals may become a speculative penny stock | |
| Neurobo Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 7 K. Net Loss for the year was (12.47 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Neurobo Pharmaceuticals currently holds about 8.85 M in cash with (10.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.96, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 65.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Neurobo Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Neurobo Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Neurobo Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Neurobo Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Neurobo Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Neurobo Pharmaceuticals' stock. These opinions can provide insight into Neurobo Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Other Consideration for investing in Neurobo Stock
If you are still planning to invest in Neurobo Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neurobo Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |